Latest Regulatory Risks News

Patrys Limited has acquired Reliis, gaining a promising injectable formulation of quetiapine aimed at treating delirium with a rapid FDA approval pathway. This move positions Patrys at the forefront of addressing a significant unmet medical need in critical care.

Highfield Resources has secured a A$10 million investment from existing strategic shareholders, extending its financial runway through early 2027 while awaiting a critical Spanish Supreme Court ruling on its Goyo mining permit appeal.

AUB Group Limited has announced the acquisition of a 95.9% stake in UK-based PIHL Holdings Limited (Prestige) for AUD 432 million, significantly expanding its UK retail insurance broking footprint. To fund this strategic move, AUB is launching a fully underwritten AUD 400 million institutional placement alongside a share purchase plan.

Legacy Minerals has locked in $4 million through an underwriting agreement to ensure full exercise of its listed options, bolstering its cash reserves to $10 million for advancing exploration at Mt Carrington.

VHM Limited has made significant strides in developing its Goschen Rare Earths and Mineral Sands Project, securing substantial funding and critical regulatory approvals while expanding its resource base.

Mayfield Childcare Limited’s board has issued a Target’s Statement recommending shareholders reject Embark Early Education’s unsolicited takeover offer, citing undervaluation and significant risks. The offer, which includes a scrip or cash option, is seen as opportunistically timed amid Mayfield’s operational turnaround.

Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.

Auris Minerals Limited has been queried by the ASX following a sharp rise in its share price and trading volume, with the company denying any undisclosed information behind the surge.

Memphasys Limited has completed a $579K shortfall placement, boosting total funds raised to over $1.12 million to support the commercial rollout of its Felix™ System following recent regulatory approvals.

Proteomics International Laboratories has achieved the prestigious CAP accreditation for its US lab and installed a new mass spectrometry platform, setting the stage for the 2026 launch of its Promarker diagnostic tests in America.

Dimerix secures FDA confirmation that proteinuria reduction is a valid primary endpoint for its Phase 3 ACTION3 trial, advancing its kidney disease drug DMX-200 closer to approval.

Neurizon Therapeutics has launched a A$24.2 million equity raise to fund the next phase of clinical trials for its lead drug NUZ-001 targeting ALS, supported by a global licensing deal and a flexible convertible note facility.